Arrighi J F, Zubler R, Hauser C, Irion O, Brouwers N, Chapuis B, Kindler V
Allergology Unit, Division of Immunology and Allergology, Geneva University Hospital, Geneva, Switzerland.
Exp Hematol. 2001 Aug;29(8):1029-37. doi: 10.1016/s0301-472x(01)00667-1.
We evaluated the frequency of hematopoietic progenitor cells (HPC) in CD34(+)CLA(+) (cutaneous lymphocyte-associated antigen) and CD34(+)CLA(-) cord blood cells, and followed cellular growth and HPC production during cultures in Flt3 ligand, thrombopoietin, and stem cell factor (FTS).
Immunomagnetic bead-purified CD34(+) cells were sorted into CD34(+)CLA(+) or CD34(+)CLA(-) cells. HPC frequency was assessed by clonal assays in methylcellulose either ex vivo or after, 7, 14, or 21 days of culture with FTS. Dendritic cell (DC) progenitors were evaluated after induction of FTS-amplified cells into DC using secondary cultures containing granulocyte-macrophage colony-stimulating factor and interleukin-4.
Ex vivo, granulocyte-macrophage progenitors were more frequent and erythroid progenitors were less frequent in the CLA(+) fraction. In FTS culture, CD34(+)CLA(+) cells produced greater absolute numbers of CD34(+) cells, granulocyte-macrophage-, erythroid-, and DC (including Langerhans cell-related) progenitors compared to CD34(+)CLA(-) cells. In CD34(+)CLA(+) cultures, CLA(+) cells steadily decreased with time, and CD34(+)CLA(-) cells appeared. In CD34(+)CLA(-) cultures, CLA(+) cells were generated, increased up to day 7, and decreased thereafter. CLA was expressed only on CD34(-) cells in these cultures. Ex vivo, CD34(+)CLA(+) cells could be subdivided further into CD38(low) and CD38(high) cells. Cord blood and growth factor-mobilized CD34(+) cells contained more CLA(+)CD38(low) cells than nonmobilized peripheral blood CD34(+) cells and proliferated more extensively with FTS than the latter cells.
CD34(+)CLA(+) cells contain a rather immature progenitor capable of high proliferation and extensive amplification of HPC in vitro. This progenitor may be localized in the CD34(+)CLA(+)CD38(low) fraction. In addition, cultures of CD34(+)CLA(+) cells from cord blood produced CD34(+)CLA(-) cells, suggesting that these cells may derive directly from CD34(+)CLA(+) cells in vivo.
我们评估了造血祖细胞(HPC)在CD34(+)CLA(+)(皮肤淋巴细胞相关抗原)和CD34(+)CLA(-)脐血细胞中的频率,并在使用Flt3配体、血小板生成素和干细胞因子(FTS)培养期间跟踪细胞生长和HPC产生情况。
通过免疫磁珠纯化的CD34(+)细胞被分选成CD34(+)CLA(+)或CD34(+)CLA(-)细胞。通过在甲基纤维素中进行克隆试验,在体外或用FTS培养7、14或21天后评估HPC频率。使用含有粒细胞-巨噬细胞集落刺激因子和白细胞介素-4的二级培养将FTS扩增的细胞诱导为树突状细胞(DC)后,评估DC祖细胞。
在体外,CLA(+)组分中粒细胞-巨噬细胞祖细胞更常见,红系祖细胞更少见。在FTS培养中,与CD34(+)CLA(-)细胞相比,CD34(+)CLA(+)细胞产生的CD34(+)细胞、粒细胞-巨噬细胞、红系和DC(包括与朗格汉斯细胞相关的)祖细胞的绝对数量更多。在CD34(+)CLA(+)培养物中,CLA(+)细胞随时间稳步减少,CD34(+)CLA(-)细胞出现。在CD34(+)CLA(-)培养物中,CLA(+)细胞产生,在第7天增加,此后减少。在这些培养物中,CLA仅在CD34(-)细胞上表达。在体外,CD34(+)CLA(+)细胞可进一步细分为CD38(低)和CD38(高)细胞。脐血和生长因子动员的CD34(+)细胞比未动员的外周血CD34(+)细胞含有更多的CLA(+)CD38(低)细胞,并且与后者相比,在FTS作用下增殖更广泛。
CD34(+)CLA(+)细胞含有一种相当不成熟的祖细胞,能够在体外高效增殖并广泛扩增HPC。这种祖细胞可能定位于CD34(+)CLA(+)CD38(低)组分中。此外,脐血中CD34(+)CLA(+)细胞的培养产生了CD34(+)CLA(-)细胞,这表明这些细胞可能在体内直接来源于CD34(+)CLA(+)细胞。